NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 55 filers reported holding NEUROCRINE BIOSCIENCES INC in Q4 2018. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $205,000 | -98.2% | 150,000 | -98.3% | 0.00% | -100.0% |
| Q2 2019 | $11,409,000 | -32.8% | 8,696,000 | -30.8% | 0.00% | -25.0% |
| Q1 2019 | $16,986,000 | +276.0% | 12,570,000 | +374.3% | 0.00% | +300.0% |
| Q3 2018 | $4,517,000 | -22.9% | 2,650,000 | -34.7% | 0.00% | 0.0% |
| Q2 2018 | $5,858,000 | – | 4,059,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Myriad Asset Management Ltd. | 17,500,000 | $29,890,000 | 4.31% |
| SSI INVESTMENT MANAGEMENT LLC | 8,987,000 | $15,319,000 | 1.18% |
| CSS LLC/IL | 14,955,000 | $25,561,000 | 1.09% |
| SHENKMAN CAPITAL MANAGEMENT INC | 3,983,000 | $6,799,000 | 0.82% |
| Verition Fund Management LLC | 6,425,000 | $10,968,000 | 0.39% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 9,495,000 | $16,214,000 | 0.33% |
| MACKAY SHIELDS LLC | 21,609,000 | $36,877,000 | 0.28% |
| WOLVERINE ASSET MANAGEMENT LLC | 12,776,000 | $21,819,000 | 0.25% |
| Calamos Advisors LLC | 24,100,000 | $41,405,000 | 0.23% |
| OAKTREE CAPITAL MANAGEMENT LP | 8,895,000 | $15,184,000 | 0.20% |